To Assess the Pharmacokinetics, Safety, and Tolerability of AZD8233 in Participants With Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD) and Healthy Participants.

NCT05065463 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped A decision has been taken to discontinue the development of AZD8233 (PCSK9-ASO for sc administration) due to low likelihood of demonstrating a benefit significantly above the current standard of care for patients with high-risk hypercholesterolemia.

Conditions

Interventions

Sponsor

AstraZeneca

Collaborators